Biotechnology
TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER
SYDNEY, April 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the company's investigational novel drug, EVT801, a selective VEGFR3 ...
2022-04-08 20:00
3850
OliX Pharmaceuticals Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate
* Identified knockdown of target genes for the NASH treatment candidate * Reduction of ALT and AST liver marker levels observed in monkey models * Company to present results at the 2022 Academic Symposium of the Korean Endocrine Society SUWON, South Korea, April 8, 2022 /PRNewswire/ -- OliX ...
2022-04-08 20:00
3658
WuXi AppTec Recognized as Top-Rated ESG Company by Sustainalytics
SHANGHAI, April 7, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, received an ESG Risk Rating, recognizing it as a "Top Rated" performing company from Sustainalytics as of March, 2022. W...
2022-04-08 08:00
2508
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr.Raffaele Baffa ("Dr. Baffa") has been appointed as...
2022-04-07 23:42
3254
SeekIn Receives CE Mark Approval for LeukoPrint® Molecular Karyotyping Test
First-of-its-Kind Molecular Karyotyping Test SHENZHEN, China, April 7, 2022 /PRNewswire/ -- SeekIn Inc, the leader in blood-based cancer early detection and monitoring technology, today announced the CE (Conformité Européenne) Mark for LeukoPrint® Molecular Karyotyping Kit and is now ready to la...
2022-04-07 22:22
2158
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced the upcoming presentation of preclinical data of H002, a next-generation epid...
2022-04-07 19:47
1894
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced a glob...
2022-04-07 09:09
2507
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
BOSTON, April 6, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston -based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, ...
2022-04-07 04:00
2544
Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US
SHENZHEN, China and LEIDEN, Netherlands, April 6, 2022 /PRNewswire/ -- Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercializes innovative medicines and CellPoint, a cell therapy company developing CAR-T therapeuti...
2022-04-06 20:30
2325
Singlera Genomics announces research collaboration with Astellas Pharma pursuing methylation-based tools to better understand biological reactions to pharmaceuticals
SAN DIEGO and TOKYO, April 5, 2022 /PRNewswire/ -- Singlera Genomics Inc. today announced a research collaboration with Astellas Pharma Inc. to develop methylation-based tools to better understand biological reactions to pharmaceuticals using Singlera's mTitan platform. mTitan allows for the int...
2022-04-05 21:56
2326
Vieworks to Make Its Debut at AACR Annual Meeting 2022 with VISQUE InVivo Series
ANYANG, South Korea, April 4, 2022 /PRNewswire/ -- Vieworks will be showcasing its optical in vivo imaging systems at AACR Annual Meeting (April 10-13, booth 2308). VISQUE InVivo Art is Vieworks' premium preclinical optical imaging system for high-sensitivity fluorescent & bioluminescent imaging ...
2022-04-04 21:00
2725
Zhongze Therapeutics Announces Successful Completion Of The First-In-Human Dose Escalation Study of ZZ6398 in Healthy Volunteers
SHANGHAI, April 1, 2022 /PRNewswire/ -- Zhongze Therapeutics, a clinical stage biotech company focused on the discovery, development and commercialization of innovative and transformative therapies for both psychiatric and neurological disorders announced today the successful completion of the fi...
2022-04-01 16:55
2011
Zhimeng Biopharma Announces Dosing of First Subject in First-in-Human Phase -- Clinical Trial of CB06
SHANGHAI, March 31, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first particip...
2022-03-31 23:40
2101
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company's key shareholders including CBC Grou...
2022-03-31 20:00
1848
CBC Group-backed Hasten Biopharma successfully completes acquisition of five cardiovascular and metabolism drugs from Takeda
* CBC Group continues to expand its global healthcare ecosystem to fulfil unmet medical needs * Hasten fast-tracks transformative medicines for patients in China SHANGHAI, March 31, 2022 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired a ...
2022-03-31 15:05
2525
LifeTech Scientific Corporation（1302.HK） Announces 2021 Annual Results
Excluding certain non-recurring items, the net profit attributable to owners of the Company increased by 76.8% to RMB 324.0million SHENZHEN, China, March 30, 2022 /PRNewswire/ -- LifeTech Scientific Corporation (LifeTech, 1302.HK), a leading company specialized in minimally invasive interventio...
2022-03-31 03:27
3924
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
- Pyxis Oncology will be responsible for development and commercialization of BSI-060T (now referred to as PYX-106), a fully human anti-Siglec-15 monoclonal antibody - Biosion earns a $10 million upfront license fee; additional milestone payments and royalties on commercial sales to be earned up...
2022-03-29 23:00
2618
CellOrigin Closed a New Round of Investment to Jump-start its iPSC Immune Cell Therapy Products Toward Clinics
HANGZHOU, China, March 29, 2022 /PRNewswire/ -- On Mar.21, 2022, CellOrigin Inc, a biotech company focusing on iPSC-derived immune cell therapies, announced it secured a new round of investment of ~100 million RMB from Jifeng Ventures, Kunlun Capital, Yinxinggu Capital and Efung Capital. CellOri...
2022-03-29 20:50
1895
Laekna Therapeutics Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board
SHANGHAI and WARREN, N.J., March 29, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage global biotechnology company，announced today the appointment of Jeff Porter, Ph.D. as the Chairman of its Scientific Advisory Board (SAB). Dr. Porter has over 25 years of global R&D leadership and strat...
2022-03-29 20:00
1958
New Video Series "PSMA PET/CT TODAY" Discusses the Future of Prostate Cancer Care with Leading Experts
MELBOURNE, Australia and INDIANAPOLIS, March 29, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the launch of PSMA PET/CT[1] Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in pr...
2022-03-29 19:00
2087
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 316 media titles]
2026-05-28 15:06Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 291 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 290 media titles]
2026-05-28 10:06Patong Stay & Dine Package at Courtyard by Marriott Phuket, Patong Beach Resort
[Picked up by 285 media titles]
2026-05-28 14:10
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7722
AMTD's Successful Completion of Acquisition of The Ritz-Carlton, Perth, Valued at A$280 Million
2026-05-29 21:50
7273
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
2026-05-28 21:14
7206
